NTRC

Precision Medicine Services. Translating science into anti-cancer drug candidates. Quality. Flexibility. Short Turnaround Time.

[NTRC @NTRC_Services]

New paper on Pharmacological validation of TDO as a target for Parkinson’s disease - by Perez‐Pardo et al. ⁦@UniUtrecht⁩ - ⁦@FEBSJournal⁩ The FEBS Journal - Wiley Online Library. NTRC is proud to be co-author. https://t.co/PwpiZ6nA09

[British Journal of Cancer @BrJCancer]

@Neil_Conlon et al. have conducted a large-scale pre-clinical comparison of the HER2-targeted tyrosine kinase inhibitors across 25 tumour tissue types identifies novel in vitro markers of response and resistance.

https://t.co/A24ytiNBnj

@coileain @ProfJohnCrown @NTRC_Services

[NTRC @NTRC_Services]

Now online in @FrontImmunol, pharmacological models to assess the role of tryptophan-metabolizing enzymes in cancer: https://t.co/uY8p4mbN9p
Congratulations to Yvonne and co-authors!

[NTRC @NTRC_Services]

Now online in @BrJCancer : Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors https://t.co/cFj4MLQSd9. @DCU @pumabiotech. Thanks @Neil_Conlon @coileain and the others for the inspirational collaboration!

[NTRC @NTRC_Services]

Accepted for publication in @FEBSJournal : Pharmacological validation of TDO as a target for Parkinson’s disease. Resulting from a research collaboration between @UniUtrecht and NTRC. You'll hear from us when it's online!

[NTRC @NTRC_Services]

Now online in @Oncotarget: Predictive approach for clinical response of ovarian cancer patients to chemotherapy treatment: https://t.co/NGAlDamM0h. The approach enables drug sensitivity testing prior to the initiation of chemotherapy treatment in a robust, easy and fast manner.

[NTRC @NTRC_Services]

@FrontImmunol has accepted our paper "Targeting indoleamine 2,3-dioxygenase in cancer models using the novel small molecule inhibitor NTRC 3883-0". You'll hear from us when it's available.

[NTRC @NTRC_Services]

Accepted for publication in @BrJCancer "Comparative analysis of drug response and gene profiling of the HER2-targeted tyrosine kinase inhibitors". Collaboration with @pumabiotech and @DCU. We'll inform you when it's online!

[NTRC @NTRC_Services]

Approved for publication in @Oncotarget: 'Chemotherapy sensitivity testing on ovarian cancer cells isolated from malignant ascites'. The paper presents an individualized, minimal invasive approach to predict chemo sensitivity at primary diagnosis. We'll keep you posted!

[NTRC @NTRC_Services]

@JordyZwet1992 and @valentina_cordo will have oral presentations at #ASH20 on December 7th, in sessions 605 and 802 respectively. NTRC’s @guido_zaman and @Jelle_cob are proud to be co-authors of the work.

[NTRC @NTRC_Services]

The power of cancer cell panel profiling for proof-of-concept studies is nicely illustrated for the small molecule NMT inhibitor PCLX-001 in @NatureComms by Erwan Beauchamp et al. @pacylex
https://t.co/GFaGHj2oZp
#Oncolines #compoundprofiling #cancer

[NTRC @NTRC_Services]

The #ENASymp20 was super inspirational and meaningful! Thanks to all speakers for sharing your work and @EORTC , @theNCI , and @AACR for the incredible organization of this virtual event.

[NTRC @NTRC_Services]

The ENA2020 virtual conference on Molecular Targets and Cancer Therapeutics #ENASymp will start tomorrow, 9:00AM EDT. Registration is free! Meet the Nobel Prize Winner Peter Ratcliffe at 12.30 EDT. @EORTC @theNCI @AACR

https://t.co/86YQ0w5UBp

[NTRC @NTRC_Services]

The ENA2020 Symposium #ENASymp will start soon! @EORTC @theNCI @AACR. NTRC proudly sponsors the virtual conference, October 24-25. You can register for free, via https://t.co/86YQ0wnvsX

[NTRC @NTRC_Services]

Investigate the mechanistic hypothesis for AMG-510 using Oncolines™ cancer cell panel profiling and bioinformatics: please join the @PerkinElmer webinar Thu, Oct 29, 2020 11:00 AM CET. https://t.co/u3KwFzKjzf

[NTRC @NTRC_Services]

Clustering analysis of recently approved #kinase inhibitors (2018-20) presented at #BostonDOT20. @guido_zaman will relate the biochemical and the cellular selectivity of e.g. BRAF, FLT3 and FGFR inhibitors. All case studies are new and have not been presented or published before.

[NTRC @NTRC_Services]

Binding curves and kinetic parameters of kinase inhibitors are available for scientists in drug discovery. Website https://t.co/aw2rhnIXEa provides for 90 kinases a link to a representative sensorgram of a single-cycle kinetic binding experiment with reference kinase inhibitor

[NTRC @NTRC_Services]

Want to know the binding characteristics of your compound to its target? Learn more on biochemical assays via https://t.co/Q0mFQBBC5Q #ResidenceTimer #QuickScout

[NTRC @NTRC_Services]

Want to find a biomarker for your drug candidate? Check https://t.co/g6emBSXHEG #Oncolines #PrecisionMedicine

[Discovery on Target @BostonDOT]

Featured presentation from the #Kinase Inhibitor Discovery track at #BostonDOT20: #Biochemical & Cellular Selectivity of All Clinically Approved Kinase Inhibitors, from @NTRC_Services' Guido Zaman. Click here to see the full agenda: https://t.co/YXGd3yRAQ1